{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:17:55Z","timestamp":1792804675941,"version":"4.5.0"},"reference-count":45,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA099908"],"award-info":[{"award-number":["R01CA099908"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA086862"],"award-info":[{"award-number":["P30CA086862"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["OC190352"],"award-info":[{"award-number":["OC190352"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002537"],"award-info":[{"award-number":["UL1TR002537"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Developing reliable experimental models that can predict clinical response before treating the patient is a high priority in gynecologic cancer research, especially in advanced or recurrent endometrial and ovarian cancers. Patient-derived organoids (PDOs) represent such an opportunity. Herein, we describe our successful creation of 43 tumor organoid cultures and nine adjacent normal tissue organoid cultures derived from patients with endometrial or ovarian cancer. From an initial set of 45 tumor tissues and seven ascites fluid samples harvested at surgery, 83% grew as organoids. Drug sensitivity testing and organoid cell viability assays were performed in 19 PDOs, a process that was accomplished within seven days of obtaining the initial surgical tumor sample. Sufficient numbers of cells were obtained to facilitate testing of the most commonly used agents for ovarian and endometrial cancer. The models reflected a range of sensitivity to platinum-containing chemotherapy as well as other relevant agents. One PDO from a patient treated prior to surgery with neoadjuvant trastuzumab successfully predicted the patient\u2019s postoperative chemotherapy and trastuzumab resistance. In addition, the PDO drug sensitivity assay identified alternative treatment options that are currently used in the second-line setting. Our findings suggest that PDOs could be used as a preclinical platform for personalized cancer therapy for gynecologic cancer patients.<\/jats:p>","DOI":"10.3390\/cancers13122901","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T13:31:39Z","timestamp":1623331899000},"page":"2901","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing"],"prefix":"10.3390","volume":"13","author":[{"given":"Jianling","family":"Bi","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7591-2483","authenticated-orcid":false,"given":"Andreea M.","family":"Newtson","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-8604","authenticated-orcid":false,"given":"Eric J.","family":"Devor","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA"},{"name":"Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan I.","family":"Samuelson","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8295-864X","authenticated-orcid":false,"given":"Kristina W.","family":"Thiel","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA"},{"name":"Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly K.","family":"Leslie","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA"},{"name":"Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Cornelison, R., Llaneza, D.C., and Landen, C.N. (2017). Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18102171"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4498-z","article-title":"Changes in ovarian cancer survival during the 20 years before the era of targeted therapy","volume":"18","author":"Lee","year":"2018","journal-title":"BMC Cancer"},{"key":"ref_3","first-page":"135","article-title":"The American Cancer Society\u2019s Facts & Figures: 2020 Edition","volume":"11","author":"Viale","year":"2020","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.2217\/fon.14.192","article-title":"USA Endometrial Cancer Projections to 2030: Should we be concerned?","volume":"10","author":"Sheikh","year":"2014","journal-title":"Future Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1758835918768232","DOI":"10.1177\/1758835918768232","article-title":"First-line treatment of ovarian cancer: Questions and controversies to address","volume":"10","author":"Ledermann","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-3-319-43139-0_2","article-title":"Clinical Behavior and Treatment of Endometrial Cancer","volume":"943","author":"Gupta","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1179299X19860815","DOI":"10.1177\/1179299X19860815","article-title":"Chemotherapy Resistance in Advanced Ovarian Cancer Patients","volume":"11","author":"Pokhriyal","year":"2019","journal-title":"Biomark. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3322\/caac.21561","article-title":"Current recommendations and recent progress in endometrial cancer","volume":"69","author":"Brooks","year":"2019","journal-title":"CA A Cancer J. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.18632\/oncotarget.14021","article-title":"Chemoresistance and targeted therapies in ovarian and endometrial cancers","volume":"8","author":"Brasseur","year":"2016","journal-title":"Oncotarget"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.semcancer.2020.02.013","article-title":"Small-molecule drug repurposing to target DNA damage repair and response pathways","volume":"68","author":"Brinkman","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: Update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2021.01.025","article-title":"Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced\/recurrent endometrial cancer: An NRG Oncology study","volume":"161","author":"Leslie","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","article-title":"Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine","volume":"7","author":"Pauli","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Leslie, K.K., Thiel, K.W., Benbrook, D.M., and Mutch, D. (2020). The Dawning of the Age of Personalized Medicine in Gynecologic Oncology. Cancers, 12.","DOI":"10.3390\/cancers12113135"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"107762","DOI":"10.1016\/j.celrep.2020.107762","article-title":"Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses","volume":"31","author":"Hami","year":"2020","journal-title":"Cell Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"eaay2574","DOI":"10.1126\/scitranslmed.aay2574","article-title":"Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients","volume":"11","author":"Ooft","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1158\/1078-0432.CCR-18-3590","article-title":"Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation","volume":"25","author":"Pasch","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ygyno.2019.11.020","article-title":"Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer","volume":"156","author":"Collins","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41556-019-0360-z","article-title":"Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening","volume":"21","author":"Boretto","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","article-title":"An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity","volume":"25","author":"Kopper","year":"2019","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-019-0305-x","article-title":"A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids","volume":"2","author":"Phan","year":"2019","journal-title":"Commun. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev-pharmtox-010818-021108","article-title":"Organoids for Drug Discovery and Personalized Medicine","volume":"59","author":"Takahashi","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/GRF.0000000000000516","article-title":"Characterization of a TP53 Somatic Variant of Unknown Function from an Ovarian Cancer Patient Using Organoid Culture and Computational Modeling","volume":"63","author":"Bi","year":"2020","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.6004\/jnccn.2019.0044","article-title":"NCCN Guidelines Insights: Genetic\/Familial High-Risk Assessment: Colorectal, Version 2.2019","volume":"17","author":"Gupta","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3747\/co.24.3824","article-title":"Systemic Therapy for Recurrent Epithelial Ovarian Cancer: A Clinical Practice Guideline","volume":"24","author":"Francis","year":"2017","journal-title":"Curr. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000510690","article-title":"Endometrial Cancer: When Upfront Surgery Is Not an Option","volume":"99","author":"Barcellini","year":"2021","journal-title":"Oncology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"849","DOI":"10.12688\/f1000research.17408.1","article-title":"Recent advances in endometrial cancer: A review of key clinical trials from 2015 to 2019","volume":"8","author":"Charo","year":"2019","journal-title":"F1000Research"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","article-title":"Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel","volume":"63","author":"Shapiro","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"Huinink","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41580-020-0259-3","article-title":"Human organoids: Model systems for human biology and medicine","volume":"21","author":"Kim","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2019.05.005","article-title":"Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors","volume":"154","author":"Maru","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1097\/IGC.0000000000001061","article-title":"The Use of Endometrial Cancer Patient\u2013Derived Organoid Culture for Drug Sensitivity Testing Is Feasible","volume":"27","author":"Girda","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ygyno.2020.03.026","article-title":"Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma","volume":"157","author":"Chen","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","article-title":"Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids","volume":"8","author":"Hill","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","article-title":"Organoids in cancer research","volume":"18","author":"Drost","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41578-021-00279-y","article-title":"Engineering organoids","volume":"6","author":"Hofer","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.tibtech.2017.12.005","article-title":"Personalized Cancer Medicine: An Organoid Approach","volume":"36","author":"Es","year":"2018","journal-title":"Trends Biotechnol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","article-title":"Prospective derivation of a living organoid biobank of colorectal cancer patients","volume":"161","author":"Francies","year":"2015","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.stem.2016.04.003","article-title":"A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis","volume":"18","author":"Fujii","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_45","first-page":"576","article-title":"Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia","volume":"569","author":"Gaiti","year":"2019","journal-title":"Nat. Cell Biol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/12\/2901\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:12:50Z","timestamp":1760163170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/12\/2901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":45,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["cancers13122901"],"URL":"https:\/\/doi.org\/10.3390\/cancers13122901","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]}}}